Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more
Omeros Corporation (OMER) - Total Assets
Latest total assets as of September 2025: $185.71 Million USD
Based on the latest financial reports, Omeros Corporation (OMER) holds total assets worth $185.71 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Omeros Corporation - Total Assets Trend (2007–2024)
This chart illustrates how Omeros Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Omeros Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Omeros Corporation's total assets of $185.71 Million consist of 48.4% current assets and 51.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.2% |
| Accounts Receivable | $36.82 Million | 13.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Omeros Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Omeros Corporation's current assets represent 48.4% of total assets in 2024, a decrease from 90.1% in 2007.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2024, down from 21.8% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 13.3% of total assets.
Omeros Corporation Competitors by Total Assets
Key competitors of Omeros Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Omeros Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Omeros Corporation generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Omeros Corporation is currently not profitable relative to its asset base.
Omeros Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.89 | 2.96 | 4.12 |
| Quick Ratio | 0.89 | 2.96 | 1.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.95 Million | $ 109.30 Million | $ 114.55 Million |
Omeros Corporation - Advanced Valuation Insights
This section examines the relationship between Omeros Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.44 |
| Latest Market Cap to Assets Ratio | 2.78 |
| Asset Growth Rate (YoY) | -26.8% |
| Total Assets | $277.08 Million |
| Market Capitalization | $768.96 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Omeros Corporation's assets at a significant premium ( 2.78x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Omeros Corporation's assets decreased by 26.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Omeros Corporation (2007–2024)
The table below shows the annual total assets of Omeros Corporation from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $277.08 Million | -26.75% |
| 2023-12-31 | $378.27 Million | -35.99% |
| 2022-12-31 | $590.97 Million | +40.95% |
| 2021-12-31 | $419.27 Million | +131.59% |
| 2020-12-31 | $181.04 Million | +32.18% |
| 2019-12-31 | $136.97 Million | +42.77% |
| 2018-12-31 | $95.94 Million | -17.53% |
| 2017-12-31 | $116.33 Million | +72.91% |
| 2016-12-31 | $67.28 Million | +37.32% |
| 2015-12-31 | $48.99 Million | +341.79% |
| 2014-12-31 | $11.09 Million | -32.93% |
| 2013-12-31 | $16.54 Million | -37.78% |
| 2012-12-31 | $26.57 Million | -1.51% |
| 2011-12-31 | $26.98 Million | -40.96% |
| 2010-12-31 | $45.70 Million | -26.36% |
| 2009-12-31 | $62.06 Million | +186.25% |
| 2008-12-31 | $21.68 Million | -20.18% |
| 2007-12-31 | $27.16 Million | -- |